IgG antibodies that recognize epitope Gly40-Arg43 in domain I of beta 2-glycoprotein I cause LAC, and their presence correlates strongly with thrombosis.

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Blood

• Publication date

  2005-02-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1182/BLOOD-2004-09-3387PMID 15507529
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• beta2-glycoprotein I-dependent lupus anticoagulant highly correlates with thrombosis in the antiphospholipid syndrome.

  2004cited by this paper
• beta2-glycoprotein I, the playmaker of the antiphospholipid syndrome.

  2004cited by this paper
• A simple method to discriminate between β2‐glycoprotein I‐ and prothrombin‐dependent lupus anticoagulants

  2003cited by this paper
• Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients.

  2002cited by this paper
• The antiphospholipid syndrome.

  2002cited by this paper
• Use of Single Point Mutations in Domain I of β2-Glycoprotein I to Determine Fine Antigenic Specificity of Antiphospholipid Autoantibodies1

  2002cited by this paper
• β2-glycoprotein I-dependent Anticardiolipin Antibodies Preferentially Bind the Amino Terminal Domain of β2-glycoprotein I

  2001cited by this paper
• Beta2-glycoprotein I-dependent anticardiolipin antibodies preferentially bind the amino terminal domain of beta2-glycoprotein I.

  2001cited by this paper
• Links between the immune and coagulation systems: How do “antiphospholipid antibodies” cause thrombosis?

  2000cited by this paper
• A hydrophobic sequence at position 313-316 (Leu-Ala-Phe-Trp) in the fifth domain of apolipoprotein H (beta2-glycoprotein I) is crucial for cardiolipin binding.

  2000cited by this paper
• Epitope studies with anti-beta 2-glycoprotein I antibodies from autoantibody and immunized sources.

  2000cited by this paper
• Prevention of experimental antiphospholipid syndrome and endothelial cell activation by synthetic peptides.

  1999cited by this paper
• International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop.

  1999cited by this paper
• 抗β2糖蛋白質I(β2GPI)自己抗体はβ2GPIの第一ドメイン上のエピトープを認識する

  1998cited by this paper
• Heterogeneity and Immunochemical Properties of Anti-β2-glycoprotein I Autoantibodies

  1998cited by this paper
• Target recognition of beta2-glycoprotein I (beta2GPI)-dependent anticardiolipin antibodies: evidence for involvement of the fourth domain of beta2GPI in antibody binding.

  1998cited by this paper
• Detection of anti-recombinant ββ2-glycoprotein 1 and anti-recombinant ββ2-glycoprotein 1 fifth-domain antibodies in sera from patients with systemic lupus erythematosus

  1998cited by this paper
• Anti-beta2 glycoprotein I (beta2GPI) autoantibodies recognize an epitope on the first domain of beta2GPI.

  1998cited by this paper
• Epitopes on β2-GPI recognized by anticardiolipin antibodies

  1998cited by this paper
• Target Recognition of β2-Glycoprotein I (β2GPI)-Dependent Anticardiolipin Antibodies: Evidence for Involvement of the Fourth Domain of β2GPI in Antibody Binding

  1998cited by this paper
• Anti-β2 glycoprotein I (β2GPI) autoantibodies recognize an epitope on the first domain of β2GPI

  1998cited by this paper
• Site-directed mutagenesis of recombinant human beta 2-glycoprotein I identifies a cluster of lysine residues that are critical for phospholipid binding and anti-cardiolipin antibody activity.

  1996cited by this paper
• Lupus Anticoagulant is the Strongest Risk Factor for both Venous and Arterial Thrombosis in Patients with Systemic Lupus Erythematosus

  1996cited by this paper
• The antiphospholipid syndrome

  1995cited by this paper
• Autoantibodies to phospholipid-binding plasma proteins: a new view of lupus anticoagulants and other "antiphospholipid" autoantibodies.

  1994cited by this paper
• The fifth domain of beta 2-glycoprotein I contains a phospholipid binding site (Cys281-Cys288) and a region recognized by anticardiolipin antibodies.

  1994cited by this paper
• Activity, disulphate mapping and structural modelling of the fifth domain of human β2‐glycoprotein I

  1992cited by this paper
• Activity, disulphide mapping and structural modelling of the fifth domain of human beta 2-glycoprotein I.

  1992cited by this paper
• Complete nucleotide and deduced amino acid sequence of human beta 2-glycoprotein I.

  1991cited by this paper
• Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H).

  1990cited by this paper
• Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease.

  1990cited by this paper
• Coagulation screen is more specific than the anticardiolipin antibody ELISA in defining a thrombotic subset of lupus patients.

  1988cited by this paper
• Immunological specificity and mechanism of action of IgG lupus anticoagulants.

  1987cited by this paper

• Comprehensive Review of Antiphospholipid Syndrome: Over Four Decades of Advances and Challenges.

  2026cites this paper
• Recurrent Pregnancy Loss

  2025cites this paper
• Lupus Anticoagulant and Anti-Prothrombin Antibodies: Embracing the Future.

  2025cites this paper
• Beyond Arg39: new insights into antiphospholipid antibodies.

  2025cites this paper
• Domain and Residue Mapping of Autoantibodies to β2GPI Reveals Differences Among Antiphospholipid Syndrome Phenotypes.

  2025cites this paper
• Diagnosis of Antiphospholipid Syndrome by Chemiluminescent or Enzyme-Linked Immunosorbent Assay – A Comparison Study and Comprehensive Literature Review

  2025cites this paper
• Anti-β2 glycoprotein domain 1 antibody as a diagnostic marker for antiphospholipid syndrome and a predictor of thrombosis: a systematic review and meta-analysis

  2025cites this paper
• The J-shape of β2GPI reveals a cryptic discontinuous epitope across domains I and II

  2025cites this paper
• Development of betabodies: The next generation of phosphatidylserine targeting agents

  2024cites this paper
• Clinical and Serological Findings of Patients with Antiphospholipid Syndrome in Mashhad, Iran, from 2008 to 2018: A Retrospective, Descriptive, Cross-sectional Study

  2024cites this paper
• The impact of antiphospholipid antibodies/antiphospholipid syndrome on systemic lupus erythematosus.

  2024cites this paper
• Detection frequency and duration of circulating antiphospholipid syndrome markers in patients with verified COVID-19

  2024cites this paper
• Laboratory Profile of Lupus Anticoagulant Positive Cases and its Association with Clinical Presentation- Experience from a Tertiary Care Centre in Southern India

  2024cites this paper
• Biological markers of high risk of thrombotic recurrence in patients with antiphospholipid syndrome: A literature review.

  2024cites this paper
• Understanding the structure of β2-glycoprotein I: new insights and future paths for antiphospholipid syndrome

  2024cites this paper
• Antiphospholipid antibodies in chronic thromboembolic pulmonary hypertension.

  2023cites this paper
• Anti-β2GPI-domain I antibody is associated with extra-criteria manifestations in a large prospective antiphospholipid syndrome cohort in China

  2023cites this paper
• An Antiphospholipid Antibody Profile as a Biomarker for Thrombophilia in Systemic Lupus Erythematosus

  2023cites this paper
• Evolution of Antiphospholipid Syndrome

  2023cites this paper
• ADAMTS13 conformation influences autoimmune recognition in immune thrombotic thrombocytopenic purpura.

  2023cites this paper
• 16th International congress on antiphospholipid antibodies task force report on antiphospholipid syndrome laboratory diagnostics and trends

  2023cites this paper
• Laboratory Testing for Non-criteria Antiphospholipid Antibodies: Antibodies Toward the Domain I of Beta2-Glycoprotein I (aDI).

  2023cites this paper
• Anti-β2-glycoprotein I and anti-phosphatidylserine/prothrombin antibodies interfere with cleavage of factor V(a) by activated protein C.

  2023cites this paper
• Association of anti-β2-glycoprotein I/HLA-DR complex antibody with arterial thrombosis in female patients with systemic rheumatic diseases

  2023cites this paper
• Structural analyses of β2-glycoprotein I: is there a circular conformation?

  2023cites this paper
• Antiphospholipid Syndrome in Patients with Venous Thromboembolism

  2022cites this paper
• Laboratory Diagnosis of Antiphospholipid Syndrome: Insights and Hindrances

  2022cites this paper
• The trends in the incidence and thrombosis-related comorbidities of antiphospholipid syndrome: a 14-year nationwide population-based study

  2022cites this paper
• Epitope of antiphospholipid antibodies retrieved from peptide microarray based on R39‐R43 of β2‐glycoprotein I

  2022cites this paper
• Antibodies to Domain I β2-Glycoprotein 1 in Patients with Antiphospholipid Syndrome and Systemic Lupus Erythematosus

  2022cites this paper
• IgG fractions from patients with antiphospholipid syndrome and systemic lupus erythematosus bind to platelets, but do not affect collagen-induced platelet activation

  2022cites this paper
• An allosteric redox switch in domain V of β2-glycoprotein I controls membrane binding and anti-domain I autoantibody recognition

  2021cites this paper
• Physical properties as antigenic determinant: the example of antiphospholipid antibodies

  2021cites this paper
• Association between plasmatic oxidative stress and thrombosis in primary antiphospholipid syndrome

  2021cites this paper
• Risk Assessment and Antithrombotic Strategies in Antiphospholipid Antibody Carriers

  2021cites this paper
• B cells in primary antiphospholipid syndrome: Review and remaining challenges.

  2021cites this paper
• Arterial and Venous Thrombosis as a Symptom of Antiphospholipid Syndrome – A Noticeable Analysis from the Past.

  2021cites this paper
• Pathophysiology of Antiphospholipid Syndrome

  2021cites this paper
• Clinical relevance of nitrated beta 2-glycoprotein I in antiphospholipid syndrome: Implications for thrombosis risk.

  2021cites this paper
• Anti‐β2‐glycoprotein I and anti‐prothrombin antibodies cause lupus anticoagulant through different mechanisms of action

  2021cites this paper
• Cardiolipin interacts with beta‐2‐glycoprotein I and forms an open conformation–Mechanisms analyzed using hydrogen/deuterium exchange

  2021cites this paper
• Anti-beta 2 glycoprotein 1 domain IgA positive antiphospholipid syndrome secondary to incomplete Behcet's disease: a case report.

  2021cites this paper
• Βeta-2-glycoprotein I exerts antithrombotic function through its domain V in mice.

  2021cites this paper
• Thrombosis and Haemostasis Pathophysiology of the Antiphospholipid Antibody Syndrome

  2021cites this paper
• Effects of anti‐beta 2‐glycoprotein 1 antibodies and its association with pregnancy‐related morbidity in antiphospholipid syndrome

  2021cites this paper
• Differences in Endothelial Activation and Dysfunction Induced by Antiphospholipid Antibodies Among Groups of Patients With Thrombotic, Refractory, and Non-refractory Antiphospholipid Syndrome

  2021cites this paper
• Snake Venoms in Diagnostic Hemostasis and Thrombosis

  2021cites this paper
• Laboratory Approaches to Test the Function of Antiphospholipid Antibodies

  2021cites this paper
• Extra criterial antiphospholipid antibodies in patients with antiphospholipid syndrome and systemic lupus erythematosus (preliminary data)

  2021cites this paper
• Assessment of Anti-β2 glycoprotein1 antibody in Systemic Lupus Erythrematosus Patients.

  2021cites this paper
• The J-elongated conformation of β2-glycoprotein I predominates in solution: implications for our understanding of antiphospholipid syndrome

  2020cites this paper
• How to Interpret Antiphospholipid Laboratory Tests

  2020cites this paper
• The role of beta-2-glycoprotein I in health and disease associating structure with function: More than just APS

  2020cites this paper
• Shedding of soluble glycoprotein VI is neither affected by animal-derived antibeta-2-glycoprotein 1 antibodies nor IgG fractions from patients with systemic lupus erythematosus.

  2020cites this paper
• X-ray and solution structures of human beta-2 glycoprotein I reveal a new mechanism of autoantibody recognition

  2020cites this paper
• Antiphospholipid autoantibody detection is important in all patients with systemic autoimmune diseases.

  2020cites this paper
• The antiphospholipid syndrome – often overlooked cause of vascular occlusions?

  2020cites this paper
• Tetra positive thrombotic antiphospholipid syndrome: Major contribution of anti‐phosphatidyl‐serine/prothrombin antibodies to lupus anticoagulant activity

  2020cites this paper
• Antiphospholipid Syndrome.

  2020cites this paper
• Elevated IgA antiphospholipid antibodies in healthy pregnant women in Sudan but not Sweden, without corresponding increase in IgA anti-β2 glycoprotein I domain 1 antibodies

  2020cites this paper
• High IgA antiphospholipid autoantibodies in healthy Sudanese explain the increased prevalence among Sudanese compared to Swedish systemic lupus erythematosus patients

  2020cites this paper
• Cardiovascular disease and antiphospholipid syndrome: how to predict and how to treat?

  2020cites this paper
• Anti-DNA antibodies cross-reactive with β2-glycoprotein I induce monocyte tissue factor through the TLR9 pathway

  2020cites this paper
• 16th International Congress on Antiphospholipid Antibodies Task Force Report on Obstetric Antiphospholipid Syndrome

  2020cites this paper
• Immunoglobulin A Isotype of Antiphospholipid Antibodies Does Not Provide Added Value for the Diagnosis of Antiphospholipid Syndrome in a Chinese Population

  2020cites this paper
• Global antiphospholipid syndrome score and anti-ß2-glycoprotein I domain I for thrombotic risk stratification in antiphospholipid syndrome: A four-year prospective study

  2020cites this paper
• Molecular Mechanisms of “Antiphospholipid Antibodies” and Their Paradoxical Role in the Pathogenesis of “Seronegative APS”

  2020cites this paper
• [Seronegative antiphospholipid syndrome: Myth or reality?]

  2020cites this paper
• Diagnostic Pitfalls in Immunology Testing.

  2019cites this paper
• News and meta-analysis regarding anti-Beta 2 glycoprotein I antibodies and their determination.

  2019cites this paper
• Pathogenic Autoreactive T and B Cells Cross-React with Mimotopes Expressed by a Common Human Gut Commensal to Trigger Autoimmunity.

  2019cites this paper
• Managing pregnancy-associated clinical emergencies in systemic lupus erythematosus: a case-based approach

  2019cites this paper
• Role of TLR-4 in anti-β2-glycoprotein I-induced activation of peritoneal macrophages and vascular endothelial cells in mice

  2019cites this paper
• Pathogenesis of Antiphospholipid Antibody Syndrome

  2019cites this paper
• Anti-domain 1 of beta2-glycoprotein I aids risk stratification in lupus anticoagulant-positive patients

  2019cites this paper
• Antiphospholipid Syndrome

  2019cites this paper
• Anti-β2GPI antibodies enhance atherosclerosis in ApoE-deficient mice.

  2019cites this paper
• Oral administration of Domain-I of beta-2glycoprotein-I induces immunological tolerance in experimental murine antiphospholipid syndrome.

  2019cites this paper
• Detection of Anti-Cardiolipin and Anti-β2glycoprotein I Antibodies Differs between Platforms without Influence on Association with Clinical Symptoms

  2019cites this paper
• Detection of anti‐domain I antibodies by chemiluminescence enables the identification of high‐risk antiphospholipid syndrome patients: A multicenter multiplatform study

  2019cites this paper
• Laboratory Evaluation of Antiphospholipid Syndrome: An Update on Autoantibody Testing.

  2019cites this paper
• Discovery and characterization of 2 novel subpopulations of aPS/PT antibodies in patients at high risk of thrombosis.

  2019cites this paper
• Insights into the diagnosis and pathogenesis of the antiphospholipid syndrome.

  2019cites this paper
• [Laboratory diagnosis of antiphospholipid syndrome: From criteria to practice].

  2018cites this paper
• Oxidative post-translational modification of βeta 2-glycoprotein I in the pathophysiology of the anti-phospholipid syndrome.

  2018cites this paper
• Obstetric Anti-phospholipid Syndrome: State of the Art

  2018cites this paper
• Anticoagulating patients with high-risk acquired thrombophilias.

  2018cites this paper
• Total Joint Arthroplasty in Patients with Inflammatory Rheumatic Diseases

  2018cites this paper
• Update on Antiphospholipid Syndrome: Ten Topics in 2017

  2018cites this paper
• Anticoagulating patients with high-risk acquired thrombophilias.

  2018cites this paper
• Lupus anticoagulant identifies two distinct groups of patients with different antibody patterns.

  2018cites this paper
• Laboratory criteria for antiphospholipid syndrome: communication from the SSC of the ISTH

  2018cites this paper
• Role of anti-domain I β2-glycoprotein I antibodies measured by different methods, in the diagnosis and risk stratification of antiphospholipid syndrome Subcommittee on Lupus anticoagulant/ antiphospholipid antibodies

  2018cites this paper
• Diagnostics and treatment of thrombotic antiphospholipid syndrome (APS): A personal perspective.

  2018cites this paper
• Prevalence and Significance of Non-conventional Antiphospholipid Antibodies in Patients With Clinical APS Criteria

  2018cites this paper
• Antiphospholipid syndrome: An update on risk factors for pregnancy outcome.

  2018cites this paper
• Recent Developments in Antiphospholipid Antibodies and the Antiphospholipid Syndrome

  2018cites this paper
• β2-Glycoprotein I-Reactive T Cells in Autoimmune Disease

  2018cites this paper
• Antiphospholipid syndrome

  2018cites this paper
• Anti-phospholipid IgG antibodies detected by line immunoassay differentiate patients with anti-phospholipid syndrome and other autoimmune diseases

  2018cites this paper